US pharmaceutical firm Eli Lilly on Wednesday said its experimental drug for Covid-19 appeared to reduce the need for hospital treatment during a trial on patients with mild and moderate symptoms.The drug maker tested three different doses of the monoclonal antibody treatment, LY-CoV555, against a placebo in a trial involving people who had recently been diagnosed with the disease.Antibodies are proteins the body makes in response to invasion by a foreign substance such as a virus. The…